XTalks

FEBRUARY 19, 2025

XTALKS WEBINAR: Key Strategies for Successful Orphan Drug Launch in Europe Live and On-Demand: Friday, March 28, 2025, at 1pm EDT (5pm GMT) Register for this free webinar to learn about optimizing pricing and reimbursement strategies and leveraging patient advocacy for a successful market launch of orphan drugs.

FDA Approval 59

FDA Approval Drugs Trials Clinical Trials 59

World of DTC Marketing

JANUARY 24, 2022

The amount of money required to gain approval of a new drug has been hotly debated, but it also costs a hell of a lot of money to launch a drug in today’s market. A study in 2020 estimated that the median cost of getting a new drug into the market was $985 million, and the average price was $1.3 Only about $2.2

Life Science 225

Life Science Drugs Development Genetic Disease 225

XTalks

NOVEMBER 28, 2023

This liquid formulation of metronidazole is the sole FDA-approved liquid option, offering a groundbreaking prescribing alternative for patients encountering difficulties in swallowing or facing taste-related obstacles. With a 24-month shelf life and no need for refrigeration, Likmez provides a convenient option for patients.

FDA Approval 103

FDA Approval Bacteria DNA Drugs 103

XTalks

OCTOBER 22, 2021

In July 2021, the agency approved the first interchangeable biosimilar product, Semglee (insulin glargine-yfgn) for the treatment of diabetes. The FDA approved the supplemental Biologics License Application (sBLA) for Cyltezo as the first interchangeable biosimilar with Humira. Cyltezo and the Emerging Humira Biosimilars Market.

FDA Approval 98

FDA Approval Production Insulin Antibody 98

XTalks

NOVEMBER 25, 2024

Shorla Oncology has received US Food and Drug Administration (FDA) approval for Imkeldi, an oral solution of imatinib designed to treat specific forms of leukemia and other cancers. Imkeldi introduces an accessible alternative to traditional tablets, particularly for those who struggle with swallowing or require customized dosing.

In-Vivo 105

In-Vivo FDA Approval In-Vitro Drugs 105

Pharmaceutical Technology

MARCH 14, 2023

Biopharmaceutical firm Cingulate and life sciences commercialisation firm Indegene have entered into a joint commercialisation deal for the former’s attention-deficit/hyperactivity disorder (ADHD) therapy CTx-1301 (dexmethylphenidate).

FDA Approval 147

FDA Approval Life Science Sales Marketing 147

XTalks

NOVEMBER 27, 2024

Syndax Pharmaceuticals’ Revuforj (revumenib) has won US Food and Drug Administration (FDA) approval for the treatment of relapsed or refractory (R/R) acute leukemia in patients aged one year and older who have a lysine methyltransferase 2A ( KMT2A, formerly MLL ) gene translocation.

FDA Approval 99

FDA Approval Drugs Gene Trials 99

XTalks

JANUARY 3, 2024

Wainua is the only FDA-approved drug for the treatment of ATTRv-PN that can be self-administered via an auto-injector. Approval of Wainua represents a meaningful advancement in treatment, one that gives those who are living with transthyretin-mediated amyloid polyneuropathy help managing the disease,” said Michael J.

FDA Approval 105

FDA Approval Protein RNA Clinical Trials 105

FDA Law Blog

JUNE 27, 2023

James was only one of five life sciences attorneys selected and the only food and drug lawyer to make the list. Amongst his accomplishments, Law360 considered the role James has played in leveraging little-used pathways to FDA approval for often first-ever drugs to treat rare diseases (e.g., HP&M’s Kurt R.

Life Science 81

Life Science FDA Approval Drugs Development 81

XTalks

DECEMBER 14, 2022

In this week’s Xtalks Life Science podcast episode, Ayesha and the team spoke with the co-founders and co-CEOs of Amylyx, Joshua Cohen and Justin Klee, and Amylyx’s General Manager of Canada Chris Aiello, about the recent FDA approval of the company’s ALS drug Relyvrio.

Life Science 52

Life Science FDA Approval Drugs Branding 52

XTalks

JANUARY 21, 2025

The approval makes Datroway AstraZenecas eighth new medicine since 2020, the first US approval for Daiichi Sankyo and AstraZenecas TROP2-directed ADC and the second based on their proprietary DXd technology. The FDA approval sent Daiichi Sankyos shares soaring by 8.7% to 4,437 yen, reflecting investor confidence.

Antibody 105

Antibody FDA Approval HR Trials 105

XTalks

JULY 28, 2021

Merck has scored US Food and Drug Administration (FDA) approval for its next-generation pneumonia vaccine Vaxneuvance that covers 15 different strains of the pneumococcal bacteria that causes the infection. Both shots are indicated for adults aged 18 years and older.

FDA Approval 89

FDA Approval Vaccination Vaccine Immune Response 89

XTalks

OCTOBER 16, 2024

Stelara now has a new biosimilar option on the market, as Dong-A ST’s Imuldosa (ustekinumab-srlf) has received approval from the US Food and Drug Administration (FDA) for the treatment of several autoimmune conditions. If approved, the biosimilar will be marketed in the European Union (EU).

FDA Approval 103

FDA Approval Marketing Pharmacy Development 103

XTalks

APRIL 3, 2024

While Soliris had its market launch 17 years ago with $3.2 billion in sales in 2023, Ultomiris was approved in 2018 and generated $3 billion in revenue last year. Competitors in the PNH market include Novartis, which won approval for its factor B inhibitor Fabhalta (iptacopan), the first oral pill for PNH treatment, late last year.

FDA Approval 102

FDA Approval Sales Trials Development 102

XTalks

APRIL 11, 2025

In 2024 its first year operating as a standalone global biosimilars enterprise BioconBiologics launched more than 60 products across emerging and established markets. The US approval follows earlier authorizations in Europe and Canada, where it is marketed as Abevmy (bevacizumab) and already in realworld use.

Antibody 109

Antibody Marketing Clinical Trials Clinical Trials 109

XTalks

MAY 2, 2022

This is the very first approval for a medication for the chronic version of VVC. The approval is a significant breakthrough for RVVC as it is a condition with significant unmet need. For Mycovia Pharmaceuticals , Vivjoa is the company’s first FDA-approved drug in its pipeline of novel treatments for fungal infections.

FDA Approval 98

FDA Approval Drugs Clinical Trials Clinical Trials 98

XTalks

JANUARY 26, 2023

This is the fourth US FDA approval that BeiGene has received for Brukinsa since 2019. This includes a greater focus on digital campaigns and diversifying marketing campaigns with race and ethnicity insights.

FDA Approval 97

FDA Approval Life Science Clinical Trials Clinical Trials 97

XTalks

JUNE 3, 2024

First approved in 2011, Eylea’s market value was estimated to be $8.79 Biocon and Biogen haven’t shared what their interchangeable biosimilars will cost, nor when they will be launched in the US market. In the US, Biogen will market Yesafili. It was also approved in the UK in November 2023.

FDA Approval 98

FDA Approval Sales Clinical Trials Clinical Trials 98

XTalks

OCTOBER 4, 2022

Rolvedon’s approval marks Spectrum’s transformation to a commercial-stage company with the opportunity to compete in a $2 billion dollar market, and offers a unique value proposition,” said Tom Riga, President and Chief Executive Officer of Spectrum Pharmaceuticals, in the company’s press release. How Does Rolvedon Work?

FDA Approval 98

FDA Approval Clinical Trials Clinical Trials Trials 98

XTalks

AUGUST 7, 2023

has received US Food and Drug Administration (FDA) approval for treating molluscum contagiosum in adult and pediatric patients aged two years and older in the US. Formerly known as VP-102, Ycanth is the first cantharidin formulation approved for this purpose. Another noteworthy contender is Novan Inc.’s

FDA Approval 98

FDA Approval Dermatology Trials Clinical Trials 98

XTalks

JANUARY 13, 2023

According to Polarean, Xenoview is the first and only inhaled hyperpolarized MRI contrast agent to reach the market. FDA approval represents achievement of a major milestone for Polarean’s technology.

FDA Approval 105

FDA Approval Packaging Packaging Clinical Trials 105

XTalks

MAY 5, 2022

There are four FDA-approved ADHD-specific nonstimulant drugs, namely Eli Lilly’s Strattera (atomoxetine), Shionogi’s Kapvay (clonidine), Takeda’s Intuniv (guanfacine) and now Supernus’ Qelbree (viloxazine). In 2002, Strattera became the first FDA-approved nonstimulant drug to treat ADHD in adults.

FDA Approval 98

FDA Approval Drugs Clinical Trials Clinical Trials 98

XTalks

MAY 4, 2022

In this episode, Ayesha discussed the FDA approval of Mycovia Pharmaceuticals’ Vivjoa (oteseconazole) as the first approved treatment for recurrent vulvovaginal candidiasis (RVVC) or chronic yeast infection. Hear more about the drug and the obesity drug market, which is projected to grow to $5.42 billion in 2025.

Life Science 52

Life Science FDA Approval Drugs Trials 52

XTalks

OCTOBER 22, 2024

Despite the regulatory hurdles in the US, Vyloy already has approvals in several international markets, including Japan, where it received approval from the Ministry of Health, Labour and Welfare in March. Astellas acquired Vyloy through its $1.4 billion purchase of Ganymed Pharmaceuticals in 2016.

FDA Approval 105

FDA Approval Drugs Licensing Licensing 105

XTalks

JANUARY 29, 2025

Related: Eli Lillys Kisunla (donanemab) Gets Full FDA Approval After Initial Rejection, Gears Up to Take on Leqembi Leqembi was first approved in 2023 as a monoclonal antibody targeting amyloid-beta protofibrils and plaques proteins that cause brain cell damage and cognitive decline in Alzheimers disease.

FDA Approval 66

FDA Approval Sales Antibody Protein 66

XTalks

APRIL 3, 2025

European AI med tech company AZmed received two new FDA clearances for its AI-powered chest X-ray tool, AZchest. The FDA approved AZchest applications to detect lung nodules and triage cases involving pneumothorax and pleural effusion. In 2023, the US medical imaging market was valued at approximately $10.53

Radiology 71

Radiology FDA Approval Marketing Trials 71

XTalks

JANUARY 20, 2025

Among these, mergers and acquisitions (M&As) have played a pivotal role in reshaping the industry landscape, enabling companies to bolster their portfolios, enhance R&D capabilities and expand their global market reach.

Marketing 104

Marketing Botox Life Science Pharma Companies 104

XTalks

FEBRUARY 26, 2024

XTALKS WEBINAR: On-Demand Code-Level Claims Data: Driving Actionable Insights and Efficiencies Live and On-Demand: Wednesday, April 3, 2024, at 1pm EDT (5pm GMT/UK) Register for this free webinar to learn how code-level claims data is a crucial dataset to address various needs across the life sciences and medical device landscape.

Allergies 100

Allergies FDA Approval Drugs Protein 100

Pharmaceutical Technology

FEBRUARY 6, 2023

Leading up to 2023, experts have said a company’s financial wellbeing may depend on its economic position when the market shifted. According to GlobalData, there are 25 marketed drugs for IPF available in North America. The FDA approved both drugs in 2014. In 2020, the company had raised $165.6 The post Pliant snags $287.5

Marketing 147

Marketing Clinical Trials Clinical Trials Drugs 147

XTalks

JUNE 17, 2024

Hugel, a Korean medical aesthetics company, recently announced that it has received marketing approval from the US Food and Drug Administration (FDA) for its botulinum toxin, Letybo (letibotulinumtoxinA-wlbg), for the treatment of glabellar lines. We are thrilled with the FDA’s approval of Letybo.

FDA Approval 52

FDA Approval Marketing Botox Clinical Trials 52

XTalks

AUGUST 19, 2022

After billions of dollars of investment, the company’s market valuation nosediving from nearly $10 billion in 2018 to just above $250 million currently and FDA delays, Zynteglo’s approval is the much-needed vote of confidence for bluebird. Zynteglo’s hefty price tag of $2.8

Gene Therapy 95

Gene Therapy FDA Approval Gene Clinical Trials 95

XTalks

JULY 7, 2023

Pfizer’s alopecia JAK inhibitor Litfulo (ritlecitinib) has become its fourth US Food and Drug Administration (FDA) approved product in the past several weeks. Litfulo is entering the alopecia market to rival Eli Lilly’s Olumiant (baricitinib), which was approved as the first drug for alopecia areata a year ago.

Marketing 98

Marketing FDA Approval Trials Drugs 98

XTalks

JANUARY 29, 2025

This translates to an average weight loss of 21%, which was demonstrated in clinical trials (over a period of 72 weeks) that supported Zepbounds FDA approval. Zepbound was approved in 2023 as the obesity counterpart of Eli Lillys GLP-1 blockbuster Mounjaro. And when it comes to weight loss, change is good, it ends off saying.

FDA Approval 71

FDA Approval Drugs Hormones Marketing 71

XTalks

MARCH 10, 2025

The FDA has approved Celltrions Omlyclo (omalizumab-igec) as an interchangeable product to Xolair. Omlyclo marks Celltrions fourth FDA approval in barely three months this year a significant milestone signaling the companys rapid advancement in the biosimilar space. billion by 2030.

Allergies 66

Allergies FDA Approval Antibody Trials 66

XTalks

FEBRUARY 28, 2025

Medtronic has received FDA approval for its BrainSense Adaptive Deep Brain Stimulation (aDBS) system. Related: Top 20 Publicly Traded Medical Device Companies by Market Cap in 2025 BrainSense will be available through Medtronics Percept neurostimulator implants.

FDA Approval 66

FDA Approval Trials Life Science Marketing 66

XTalks

AUGUST 22, 2022

What sets Auvelity apart from other antidepressants on the market is its ability to act rapidly. Additionally, Axsome says Auvelity is the first oral MDD medication with a new mechanism of action to hit the market in more than 60 years.

FDA Approval 98

FDA Approval Production Marketing Drugs 98

XTalks

DECEMBER 20, 2024

The US Food and Drug Administration (FDA) has approved Celltrions Steqeyma (ustekinumab-stba), a biosimilar to Stelara (ustekinumab), for the treatment of several immune-mediated diseases. Since September 2024, a new Stelara biosimilar has been approved nearly every month, reflecting a rapid shift in the global biosimilar market.

FDA Approval 52

FDA Approval Immune Response Antibody Marketing 52